PMID- 33764230
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 37
IP  - 7
DP  - 2021 Jul
TI  - Effects of sacubitril/valsartan on clinical symptoms, echocardiographic 
      parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease 
      and chronic kidney disease.
PG  - 1071-1078
LID - 10.1080/03007995.2021.1908243 [doi]
AB  - OBJECTIVE: To compare the effects of Angiotensin Receptor-Neprilysin inhibitor 
      (ARNI) on the clinical symptoms, echocardiographic parameters, and outcomes 
      (cardiovascular death and hospitalization) in heart failure with reduced ejection 
      fraction (HFrEF) and heart failure with mid-range ejection fraction (HFmrEF) 
      patients with coronary heart disease and chronic kidney disease. METHOD: A 
      retrospective observational study was conducted from January 2018 to May 2019, 
      with a follow-up period of 95.4 +/- 57.8 days (8 months). Data from 127 patients 
      were included. RESULTS: A statistically significant increase of 68.8% was 
      observed in left ventricular ejection fraction (LVEF) in HFrEF patients compared 
      to that in HFmrEF patients, with an increase of 27.2% at 8 months of follow-up. 
      Sacubitril/valsartan significantly reduced left ventricular end-systolic volumes 
      (LVESV) in HFrEF patients unlike in HFmrEF patients. The decrease in LVESV was 
      28.8% in HFrEF patients and 17.1% in HFmrEF patients. A significant reduction in 
      the prevalence of severe secondary mitral regurgitation (EROA > 0.4 cm(2)) was 
      observed in HFrEF compared to that in HFmrEF patients with the use of 
      sacubitril/valsartan. A reduction of 15.6% was observed in HFrEF patients, 
      whereas a reduction of 7.1% was observed in HFmrEF patients. Improvement in 
      functional classification (NYHA) was observed during follow-up. The prevalence of 
      (NYHA III) reduced from 50% to 15.7% in HFrEF patients, whereas a reduction from 
      21.1% to 8.8% was observed in HFmrEF patients. There was a significant reduction 
      in NT-proBNP in HFrEF patients compared to that in HFmrEF patients. A reduction 
      of 52% was observed in HFrEF patients, whereas a reduction of 28.7% was observed 
      in HFmrEF pateints. Sacubitril/valsartan reduced primary endpoint events in both 
      groups. The prevalence of HF-related hospitalization was higher in HFrEF than in 
      HFmrEF patients: 12.1% vs 7.5%, respectively. The prevalence of CV death in HFrEF 
      vs HFmrEF patients was 3.7% vs 0.5%, respectively. Cardiovascular (CV) death was 
      higher in patients with atrial fibrillation in both groups. CONCLUSION: 
      Sacubitril/valsartan significantly improved morphofunctional remodeling 
      parameters and clinical symptoms in HFrEF patients than in HFmrEF patients.
FAU - Raphael, Dominick Mkombozi
AU  - Raphael DM
AUID- ORCID: 0000-0002-0502-4058
AD  - Cardiology Department, First Affiliated Hospital of Zhengzhou University, Henan, 
      China.
FAU - Liu, Zhiyu
AU  - Liu Z
AD  - Cardiology Department, First Affiliated Hospital of Zhengzhou University, Henan, 
      China.
FAU - Jin, Zhi
AU  - Jin Z
AD  - Cardiology Department, First Affiliated Hospital of Zhengzhou University, Henan, 
      China.
FAU - Cui, Xinyue
AU  - Cui X
AD  - Cardiology Department, First Affiliated Hospital of Zhengzhou University, Henan, 
      China.
FAU - Han, Dongjian
AU  - Han D
AD  - Cardiology Department, First Affiliated Hospital of Zhengzhou University, Henan, 
      China.
FAU - He, Weiwei
AU  - He W
AD  - Cardiology Department, First Affiliated Hospital of Zhengzhou University, Henan, 
      China.
FAU - Shangguan, Jiahong
AU  - Shangguan J
AD  - Cardiology Department, First Affiliated Hospital of Zhengzhou University, Henan, 
      China.
FAU - Shen, Deliang
AU  - Shen D
AD  - Cardiology Department, First Affiliated Hospital of Zhengzhou University, Henan, 
      China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20210420
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aminobutyrates
MH  - Angiotensin Receptor Antagonists
MH  - Biphenyl Compounds
MH  - *Coronary Disease
MH  - Drug Combinations
MH  - Echocardiography
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - *Renal Insufficiency, Chronic/complications/drug therapy
MH  - Stroke Volume
MH  - Tetrazoles/therapeutic use
MH  - Valsartan
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - HFmrEF
OT  - HFrEF
OT  - chronic kidney disease
OT  - coronary heart disease
OT  - sacubitril/valsartan
EDAT- 2021/03/26 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/03/25 12:23
PHST- 2021/03/26 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/03/25 12:23 [entrez]
AID - 10.1080/03007995.2021.1908243 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2021 Jul;37(7):1071-1078. doi: 10.1080/03007995.2021.1908243. 
      Epub 2021 Apr 20.